Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4581211 | 0.82 | CYP11B2 (0.41) | CYP11B2POLBTP53MAPT | |
| SCHEMBL4581710 | 0.79 | HSP90AA1 (0.46) | CYP11B2OPRM1OPRK1OPRD1KDM4E | |
| SCHEMBL14292225 | 0.78 | OPRM1 (0.38) | CYP11B2OPRM1OPRK1OPRD1 | |
| SCHEMBL4578462 | 0.78 | CYP11B2 (0.46) | CYP11B2POLBOPRM1KDM4EALDH1A1 | |
| SCHEMBL4579645 | 0.69 | CYP11B2 (0.44) | CYP11B2POLBKDM4EALDH1A1 | |
| SCHEMBL4578947 | 0.68 | HSP90AA1 (0.44) | — | |
| SCHEMBL4580710 | 0.67 | POLB (0.37) | CYP11B2POLBOPRM1OPRK1OPRD1 | |
| SCHEMBL4581097 | 0.66 | CYP11B2 (0.41) | CYP11B2POLBKDM4EALDH1A1 | |
| SCHEMBL4582471 | 0.66 | CYP11B2 (0.42) | CYP11B2 | |
| SCHEMBL1219565 | 0.65 | KMT2A (0.51) | POLBOPRM1KDM4EALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, CCNB3 | CYP11B2 710/4885POLB 1584/4885OPRM1 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.